Targeted Oncology5d
FDA Grants Rare Pediatric Disease Designation to Galinpepimut-S in AML
The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...
Cancer Therapy Advisor5d
Galinpepimut-S Gets Rare Pediatric Disease Designation for AML
The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...
SELLAS' Galinpepimut-S Gets Rare Pediatric Disease Designation For Treatment Of Pediatric AML
SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Tuesday announced that the U.S. Food and ...
Yahoo Finance29d
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
Targeted Oncology5d
LP-184 Earns FDA Fast Track Designation in Glioblastoma
The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...
clinicalpainadvisor.com12d
Setrusumab Gets Breakthrough Tx Designation for Osteogenesis Imperfecta
The FDA has granted Breakthrough Therapy designation to setrusumab to reduce fracture risk with osteogenesis imperfecta type I, III, or IV.
manilatimes6d
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
Theriva Biologics (NYSE American: TOVX), ("Theriva” or the "Company”), a clinical-stage company developing therapeutics ...